{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:14:21Z","timestamp":1792890861664,"version":"4.5.0"},"reference-count":197,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.neuropharm.2019.04.015","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T10:47:15Z","timestamp":1555670835000},"page":"107609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"special_numbering":"C","title":["Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine"],"prefix":"10.1016","volume":"158","author":[{"given":"Chloe J.","family":"Jordan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjing","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Hauck","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Xiong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.04.015_bib1","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1021\/jm970525a","article-title":"Novel N-substituted 3 alpha-[bis(4'-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter","volume":"40","author":"Agoston","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib2","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib3","first-page":"8","article-title":"Methadone treatment of opiate addiction: a systematic review of comparative studies","volume":"14","author":"Ali","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib4","first-page":"CD003409","article-title":"Methadone at tapered doses for the management of opioid withdrawal","author":"Amato","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.drugalcdep.2011.07.007","article-title":"Modafinil for the treatment of methamphetamine dependence","volume":"120","author":"Anderson","year":"2012","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.5694\/j.1326-5377.2000.tb139323.x","article-title":"The rediscovery of methadone for cancer pain management","volume":"173","author":"Ayonrinde","year":"2000","journal-title":"Med. J. Aust."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0022-3565(25)10296-6","article-title":"Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats","volume":"264","author":"Bals-Kubik","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1006\/phrs.1999.0517","article-title":"Effects of buprenorphine on motility in morphine post-dependent rats","volume":"40","author":"Bartoletti","year":"1999","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/0028-3908(93)90141-O","article-title":"Effects of buprenorphine on motility in chronically morphine treated rats","volume":"32","author":"Bartoletti","year":"1993","journal-title":"Neuropharmacology"},{"issue":"Suppl. 8","key":"10.1016\/j.neuropharm.2019.04.015_bib10","first-page":"S235","article-title":"Cost and utilization outcomes of opioid-dependence treatments","volume":"17","author":"Baser","year":"2011","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib11","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1074\/jbc.272.2.782","article-title":"Differential opioid agonist regulation of the mouse mu opioid receptor","volume":"272","author":"Blake","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejphar.2018.08.007","article-title":"Pharmacological treatments for opiate and alcohol addiction: a historical perspective of the last 50 years","volume":"836","author":"Blanco-Gandia","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/35047086","article-title":"Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence","volume":"408","author":"Bohn","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib14","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking beta-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/0024-3205(81)90148-X","article-title":"Intracranial self-administration of morphine into the ventral tegmental area in rats","volume":"28","author":"Bozarth","year":"1981","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0006-8993(83)91232-5","article-title":"Ventral tegmental site of opiate reward: antagonism by a hydrophilic opiate receptor blocker","volume":"258","author":"Britt","year":"1983","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib17","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00213-006-0670-2","article-title":"The effects of buprenorphine on fentanyl withdrawal in rats","volume":"191","author":"Bruijnzeel","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00063110-200402000-00004","article-title":"Adverse events after naloxone treatment of episodes of suspected acute opioid overdose","volume":"11","author":"Buajordet","year":"2004","journal-title":"Eur. J. Emerg. Med."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib19","first-page":"135","article-title":"The historical development of cancer chemotherapy","volume":"4","author":"Burchenal","year":"1977","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2165\/00003088-198611020-00004","article-title":"Pharmacokinetic determinants of drug abuse and dependence. A conceptual perspective","volume":"11","author":"Busto","year":"1986","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1749-6632.2011.06352.x","article-title":"The history of the development of buprenorphine as an addiction therapeutic","volume":"1248","author":"Campbell","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib22","doi-asserted-by":"crossref","first-page":"10676","DOI":"10.1021\/acs.jmedchem.6b01373","article-title":"Novel and high affinity 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues as atypical dopamine transporter inhibitors","volume":"59","author":"Cao","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejphar.2006.09.024","article-title":"Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration","volume":"553","author":"Carroll","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib24","doi-asserted-by":"crossref","first-page":"E196","DOI":"10.1208\/aapsj080124","article-title":"Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse","volume":"8","author":"Carroll","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib25","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3389\/fphar.2018.00712","article-title":"A double-blind, placebo-controlled trial demonstrating the safety, tolerability, and pharmacokinetics of single, escalating oral doses of RTI-336","volume":"9","author":"Carroll","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib26","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1523\/JNEUROSCI.4458-13.2014","article-title":"Opioid hedonic hotspot in nucleus accumbens shell: mu, delta, and kappa maps for enhancement of sweetness \"liking\" and \"wanting","volume":"34","author":"Castro","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib27","series-title":"CDC WONDER online databases","author":"Center for Disease Control (CDC)","year":"2018"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fphar.2014.00116","article-title":"It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system","volume":"5","author":"Chartoff","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib29","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1038\/sj.npp.1301008","article-title":"Unlimited access to heroin self-administration: independent motivational markers of opiate dependence","volume":"31","author":"Chen","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib30","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1586\/14737175.2013.833002","article-title":"The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD","volume":"13","author":"Childress","year":"2013","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib31","first-page":"CD002210","article-title":"LAAM maintenance vs methadone maintenance for heroin dependence","author":"Clark","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib32","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0022-3565(25)10630-7","article-title":"Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception","volume":"274","author":"Codd","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib33","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1124\/jpet.102.038141","article-title":"Self-administration of intravenous buprenorphine and the buprenorphine\/naloxone combination by recently detoxified heroin abusers","volume":"303","author":"Comer","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib34","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1124\/jpet.301.1.266","article-title":"Intravenous buprenorphine self-administration by detoxified heroin abusers","volume":"301","author":"Comer","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib35","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1124\/jpet.105.090423","article-title":"Comparison of intravenous buprenorphine and methadone self-administration by recently detoxified heroin-dependent individuals","volume":"315","author":"Comer","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib36","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.pbb.2010.05.017","article-title":"Lower reinforcing strength of the phenyltropane cocaine analogs RTI-336 and RTI-177 compared to cocaine in nonhuman primates","volume":"96","author":"Czoty","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib37","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jsat.2011.12.014","article-title":"A double-blind, placebo-controlled trial of modafinil for cocaine dependence","volume":"43","author":"Dackis","year":"2012","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0376-8716(02)00335-6","article-title":"Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study","volume":"70","author":"Dackis","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0091-3057(94)90324-7","article-title":"Differentiation of intracranial morphine self-administration behavior among five brain regions in mice","volume":"48","author":"David","year":"1994","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib40","series-title":"About the U.S. Opioid Epidemic","author":"Department of Health and Human Services (HHS)","year":"2018"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib41","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1124\/jpet.113.208538","article-title":"Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist","volume":"348","author":"Desai","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib42","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1523\/JNEUROSCI.4778-04.2005","article-title":"Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine","volume":"25","author":"Desai","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0740-5472(02)00244-1","article-title":"Heroin detoxification with buprenorphine on an inpatient psychiatric unit","volume":"23","author":"DiPaula","year":"2002","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib44","first-page":"487","article-title":"Study of methadone as an adjunct in rehabilitation of heroin addicts","volume":"130","author":"Dole","year":"1966","journal-title":"IMJ Ill. Med. J."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib45","first-page":"2011","article-title":"Rehabilitation of heroin addicts after blockade with methadone","volume":"66","author":"Dole","year":"1966","journal-title":"N. Y. State J. Med."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ADM.0000000000000193","article-title":"A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction","volume":"10","author":"Dugosh","year":"2016","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2011.05.033","article-title":"The association between outpatient buprenorphine detoxification duration and clinical treatment outcomes: a review","volume":"119","author":"Dunn","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib48","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence","volume":"41","author":"Eap","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib49","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0006-2952(98)00088-4","article-title":"Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists","volume":"56","author":"Ebert","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib50","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1038\/npp.2016.38","article-title":"Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors","volume":"41","author":"Falcon","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib51","article-title":"E-cigarettes and smoking cessation in the United States according to frequency of e-cigarette use and quitting duration: analysis of the 2016 and 2017 National Health Interview Surveys","author":"Farsalinos","year":"2019","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib52","author":"Food and Drug Administration (FDA)"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib53","series-title":"Subutex and Suboxone Approval Letter","author":"Food and Drug Administration (FDA)","year":"2002"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib54","first-page":"1040","article-title":"Good medical practice in the care of the narcotic addict; a report prepared by a special committee appointed by the executive committee of the Canadian medical association","volume":"92","author":"Ferguson","year":"1965","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib55","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tins.2015.01.002","article-title":"Understanding opioid reward","volume":"38","author":"Fields","year":"2015","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib56","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1001\/jamainternmed.2014.5302","article-title":"Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial","volume":"174","author":"Fiellin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib57","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2307\/3343343","article-title":"Prescriptions, power and politics: the turbulent history of methadone maintenance in Canada","volume":"21","author":"Fischer","year":"2000","journal-title":"J. Public Health Policy"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1021\/jm0608614","article-title":"Slow-onset, long-duration, alkyl analogues of methylphenidate with enhanced selectivity for the dopamine transporter","volume":"50","author":"Froimowitz","year":"2007","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib59","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.pbb.2005.05.003","article-title":"Cross-tolerance and mu agonist efficacy in pigeons treated with LAAM or buprenorphine","volume":"81","author":"Galici","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib60","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/clpt.2010.307","article-title":"A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction","volume":"89","author":"Galloway","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib61","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.neuropharm.2006.06.009","article-title":"A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction","volume":"51","author":"Gardner","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib62","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/00004714-199712000-00008","article-title":"Replacement medication for cocaine dependence: methylphenidate","volume":"17","author":"Grabowski","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib63","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.addbeh.2004.06.018","article-title":"Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence","volume":"29","author":"Grabowski","year":"2004","journal-title":"Addict. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib64","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/syn.890160303","article-title":"Buprenorphine and morphine produce equivalent increases in extracellular single unit activity of dopamine neurons in the ventral tegmental area in vivo","volume":"16","author":"Grant","year":"1994","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib65","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib66","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib67","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.brainres.2005.07.012","article-title":"Cocaine self-administration and locomotor activity are altered in Lewis and F344 inbred rats by RTI 336, a 3-phenyltropane analog that binds to the dopamine transporter","volume":"1055","author":"Haile","year":"2005","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib68","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1808779","article-title":"A randomized trial of E-cigarettes versus nicotine-replacement therapy","volume":"380","author":"Hajek","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib69","series-title":"Buprenorphine Formulations for the Treatment of Opioid Use Disorders: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines","author":"Harricharan","year":"2017"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1749-6632.2009.05149.x","article-title":"Current perspectives on selective dopamine D(3) receptor antagonists as pharmacotherapeutics for addictions and related disorders","volume":"1187","author":"Heidbreder","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib71","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ejmech.2017.10.012","article-title":"Selective kappa opioid antagonists for treatment of addiction, are we there yet?","volume":"141","author":"Helal","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib72","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.113.208264","article-title":"Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats","volume":"348","author":"Hiranita","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aar4309","article-title":"G protein signaling-biased agonism at the kappa-opioid receptor is maintained in striatal neurons","volume":"11","author":"Ho","year":"2018","journal-title":"Sci. Signal."},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2019.04.015_bib74","first-page":"297S","article-title":"Analgesic effectiveness of the narcotic agonist-antagonists","volume":"7","author":"Houde","year":"1979","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib75","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0091-3057(85)90301-6","article-title":"Opiate self-administration in adult offspring of methadone-treated female rats","volume":"22","author":"Hovious","year":"1985","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib76","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1124\/jpet.106.108324","article-title":"Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys","volume":"320","author":"Howell","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib77","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0091-3057(88)90443-1","article-title":"The reinforcing properties of the mixed agonist-antagonist buprenorphine as assessed by brain-stimulation reward","volume":"30","author":"Hubner","year":"1988","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2019.04.015_bib78","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/0024-3205(83)90616-1","article-title":"Evidence from opiate binding studies that heroin acts through its metabolites","volume":"33","author":"Inturrisi","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib79","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/syn.20810","article-title":"Enhanced dendritic availability of mu-opioid receptors in inhibitory neurons of the extended amygdala in mice deficient in the corticotropin-releasing factor-1 receptor","volume":"65","author":"Jaferi","year":"2011","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib80","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib81","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0376-8716(86)90079-7","article-title":"Comparison of intravenously administered methadone, morphine and heroin","volume":"17","author":"Jasinski","year":"1986","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib82","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.tips.2018.10.002","article-title":"Utilizing buprenorphine in the emergency department after overdose","volume":"39","author":"Johns","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib83","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17460441.2018.1458090","article-title":"Discovery and development of varenicline for smoking cessation","volume":"13","author":"Jordan","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib84","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/10826084.2017.1400069","article-title":"Changing the treatment direction for opiate addiction: Dr. Dole's research","volume":"53","author":"Joseph","year":"2018","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib85","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1176\/ajp.2007.164.5.797","article-title":"A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial","volume":"164","author":"Kakko","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib86","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib87","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0014-2999(02)02700-0","article-title":"Interactions of the narcotic l-alpha-acetylmethadol with human cardiac K+ channels","volume":"458","author":"Kang","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib88","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/bs.irn.2017.08.001","article-title":"Dynorphin\/kappa opioid receptor signaling in preclinical models of alcohol, drug, and food addiction","volume":"136","author":"Karkhanis","year":"2017","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib89","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1124\/jpet.103.060525","article-title":"Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands","volume":"309","author":"Katz","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.neuropharm.2019.04.015_bib90","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1021\/acschemneuro.8b00340","article-title":"Effects of R-modafinil and modafinil analogs on dopamine dynamics assessed by voltammetry and microdialysis in the mouse nucleus accumbens shell","volume":"10","author":"Keighron","year":"2019","journal-title":"A.C.S. Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib91","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMc1809521","article-title":"Lethal fentanyl and cocaine intoxication","volume":"379","author":"Khatri","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib92","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1517\/14740338.2015.1037274","article-title":"Reducing the harm of opioid overdose with the safe use of naloxone : a pharmacologic review","volume":"14","author":"Kim","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib93","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.pbb.2008.03.032","article-title":"Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys","volume":"90","author":"Kimmel","year":"2008","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib94","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.pbb.2006.12.006","article-title":"Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys","volume":"86","author":"Kimmel","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib95","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1151\/spp021113","article-title":"The neurobiology of opioid dependence: implications for treatment","volume":"1","author":"Kosten","year":"2002","journal-title":"Sci Pract Perspect"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib96","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1749-6632.2000.tb06683.x","article-title":"Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine","volume":"909","author":"Kreek","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2019.04.015_bib97","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuropharm.2004.07.024","article-title":"Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA","volume":"47","author":"Kreek","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib98","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0740-5472(02)00259-3","article-title":"History and current status of opioid maintenance treatments: blending conference session","volume":"23","author":"Kreek","year":"2002","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib99","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1477-7517-6-4","article-title":"Opioid substitution treatment with sublingual buprenorphine in Manipur and Nagaland in Northeast India: what has been established needs to be continued and expanded","volume":"6","author":"Kumar","year":"2009","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib100","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/sj.npp.1300435","article-title":"Methadone maintenance reduces heroin- and cocaine-induced relapse without affecting stress-induced relapse in a rodent model of poly-drug use","volume":"29","author":"Leri","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib101","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.lfs.2005.05.062","article-title":"Reversal of morphine, methadone and heroin induced effects in mice by naloxone methiodide","volume":"78","author":"Lewanowitsch","year":"2006","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib102","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1124\/jpet.110.173260","article-title":"N-substituted benztropine analogs: selective dopamine transporter ligands with a fast onset of action and minimal cocaine-like behavioral effects","volume":"336","author":"Li","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib103","series-title":"Methadone Usage, Misuse, and Addiction Processes: an Overview in Neuropathology of Drug Addiction and Substance Misuse","author":"Li","year":"2016"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib104","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mcn.2007.04.007","article-title":"Distinct effects of individual opioids on the morphology of spines depend upon the internalization of mu opioid receptors","volume":"35","author":"Liao","year":"2007","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib105","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0024-3205(84)90233-9","article-title":"Methadone induced physical dependence in the rat","volume":"34","author":"Ling","year":"1984","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib106","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1360-0443.2005.01154.x","article-title":"A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network","volume":"100","author":"Ling","year":"2005","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib107","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1360-0443.2008.02455.x","article-title":"Buprenorphine tapering schedule and illicit opioid use","volume":"104","author":"Ling","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib108","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1016\/S0376-8716(03)00059-0","article-title":"Clinical efficacy of buprenorphine: comparisons to methadone and placebo","volume":"70","author":"Ling","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2019.04.015_bib109","first-page":"S29","article-title":"Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial","volume":"13","author":"Lintzeris","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib110","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00228-010-0793-6","article-title":"The pharmacological treatment of opioid addiction--a clinical perspective","volume":"66","author":"Lobmaier","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib111","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.biopsych.2012.03.022","article-title":"R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse","volume":"72","author":"Loland","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib112","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.drudis.2017.07.002","article-title":"Mu-Opioid receptor biased ligands: a safer and painless discovery of analgesics?","volume":"22","author":"Madariaga-Mazon","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib113","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.neuropharm.2017.06.019","article-title":"Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor","volume":"123","author":"Margolis","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib114","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.neuron.2014.04.030","article-title":"Separate GABA afferents to dopamine neurons mediate acute action of opioids, development of tolerance, and expression of withdrawal","volume":"82","author":"Matsui","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib115","first-page":"CD002209","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib116","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1300\/J069v21n03_01","article-title":"Optimizing long-term response to methadone maintenance treatment: a 152-week follow-up using higher-dose methadone","volume":"21","author":"Maxwell","year":"2002","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib118","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2105\/AJPH.2016.303627","article-title":"Recent increases in cocaine-related overdose deaths and the role of opioids","volume":"107","author":"McCall Jones","year":"2017","journal-title":"Am. J. Public Health"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib119","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0091-3057(81)90180-5","article-title":"Buprenorphine self-administration by rhesus monkey","volume":"15","author":"Mello","year":"1981","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib120","first-page":"172","article-title":"Buprenorphine, heroin, and methadone: comparison of relative reinforcing properties","volume":"49","author":"Mello","year":"1984","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib121","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0376-8716(88)90053-1","article-title":"Progressive ratio performance maintained by buprenorphine, heroin and methadone in Macaque monkeys","volume":"21","author":"Mello","year":"1988","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib122","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1126\/science.7352279","article-title":"Buprenorphine suppresses heroin use by heroin addicts","volume":"207","author":"Mello","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib123","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0376-8716(85)90062-6","article-title":"Behavioral pharmacology of buprenorphine","volume":"14","author":"Mello","year":"1985","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib124","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S0022-3565(25)33287-8","article-title":"Buprenorphine effects on human heroin self-administration: an operant analysis","volume":"223","author":"Mello","year":"1982","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib125","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-013-3232-4","article-title":"The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders","volume":"229","author":"Mereu","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib126","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/add.12109","article-title":"Extended-release methylphenidate for treatment of amphetamine\/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial","volume":"108","author":"Miles","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib127","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2008.10.016","article-title":"Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial","volume":"101","author":"Mooney","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib128","series-title":"CADTH Issues in Emerging Health Technologies","article-title":"Injectable extended-release naltrexone to treat opioid use disorder","author":"Ndegwa","year":"2016"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib129","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1124\/jpet.105.095380","article-title":"Choice between heroin and food in nondependent and heroin-dependent rhesus monkeys: effects of naloxone, buprenorphine, and methadone","volume":"317","author":"Negus","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib130","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.pbb.2017.04.006","article-title":"Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: implications for negative reinforcement as a driver of addiction and target for medications development","volume":"164","author":"Negus","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib131","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-019-0366-z","article-title":"Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders","author":"Newman","year":"2019","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib132","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1021\/jm401754x","article-title":"Elucidation of structural elements for selectivity across monoamine transporters: novel 2-[(diphenylmethyl)sulfinyl]acetamide (modafinil) analogues","volume":"57","author":"Okunola-Bakare","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib133","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1037\/0735-7044.111.6.1324","article-title":"The development of a conditioned place preference to morphine: effects of microinjections into various CNS sites","volume":"111","author":"Olmstead","year":"1997","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib134","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/026921639801200411","article-title":"Methadone: opioid, N-methyl-D-aspartate antagonist or both?","volume":"12","author":"Oxenham","year":"1998","journal-title":"Palliat. Med."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib135","doi-asserted-by":"crossref","first-page":"517","DOI":"10.33549\/physiolres.933183","article-title":"The effect of chronic morphine or methadone exposure and withdrawal on clock gene expression in the rat suprachiasmatic nucleus and AA-NAT activity in the pineal gland","volume":"65","author":"Pacesova","year":"2016","journal-title":"Physiol. Res."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib136","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1038\/npp.2010.133","article-title":"Is slow-onset long-acting monoamine transport blockade to cocaine as methadone is to heroin? Implication for anti-addiction medications","volume":"35","author":"Peng","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib137","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/0091-3057(80)90460-8","article-title":"Reinforcing effects of morphine microinjection into the ventral tegmental area","volume":"12","author":"Phillips","year":"1980","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib138","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neuropharm.2017.03.016","article-title":"Delta-opioid receptor antagonism leads to excessive ethanol consumption in mice with enhanced activity of the endogenous opioid system","volume":"118","author":"Poznanski","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib139","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0091-3057(82)90017-X","article-title":"Effects of parenteral morphine and oral methadone on self-stimulation in the rat","volume":"16","author":"Preshaw","year":"1982","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib140","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in beta-arrestin 2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib141","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/jpet.103.053504","article-title":"Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques","volume":"307","author":"Raje","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib142","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.12.005","article-title":"Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter","volume":"147","author":"Reith","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib143","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/WNF.0b013e3181a9163c","article-title":"The neurobiology of addictive disorders","volume":"32","author":"Ross","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib144","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1080\/10826084.2016.1276597","article-title":"Modafinil treatment of cocaine dependence: a systematic review and meta-analysis","volume":"52","author":"Sangroula","year":"2017","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib145","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1038\/npp.2017.69","article-title":"Sex differences in regional brain glucose metabolism following opioid withdrawal and replacement","volume":"42","author":"Santoro","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1139\/y86-001","article-title":"The therapeutic use of heroin: a review of the pharmacological literature","volume":"64","author":"Sawynok","year":"1986","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib147","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jfda.2013.09.037","article-title":"Medication-assisted treatment for opioid addiction: methadone and buprenorphine","volume":"21","author":"Saxon","year":"2013","journal-title":"J. Food Drug Anal."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib148","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.neuron.2012.09.026","article-title":"Stress-related neuropeptides and addictive behaviors: beyond the usual suspects","volume":"76","author":"Schank","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib149","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib150","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/j.1360-0443.2008.02437.x","article-title":"A double-blind, placebo-controlled trial of modafinil (200 mg\/day) for methamphetamine dependence","volume":"104","author":"Shearer","year":"2009","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib151","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tips.2014.11.006","article-title":"Amphetamines, new psychoactive drugs and the monoamine transporter cycle","volume":"36","author":"Sitte","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib152","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/ejn.13390","article-title":"The dopamine D3 receptor, a quarter century later","volume":"45","author":"Sokoloff","year":"2017","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib153","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/sj.npp.1300712","article-title":"Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement","volume":"30","author":"Sorge","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib154","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s00213-006-0485-1","article-title":"The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration","volume":"188","author":"Sorge","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib155","first-page":"CD000146","article-title":"Nicotine replacement therapy for smoking cessation","volume":"11","author":"Stead","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2015.04.006","article-title":"Supplemental morphine infusion into the posterior ventral tegmentum extends the satiating effects of self-administered intravenous heroin","volume":"134","author":"Steidl","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib157","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF02246167","article-title":"Orally delivered methadone as a reinforcer in rhesus monkeys","volume":"123","author":"Stewart","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib158","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/sj.npp.1300487","article-title":"Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats","volume":"30","author":"Stinus","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib159","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1460-9592.2004.01264.x","article-title":"Buprenorphine blocks withdrawal in morphine-dependent rat pups","volume":"14","author":"Stoller","year":"2004","journal-title":"Paediatr. Anaesth."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib160","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1517\/14656560903037168","article-title":"Opioid dependence treatment: options in pharmacotherapy","volume":"10","author":"Stotts","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib161","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/clpt.2010.352","article-title":"Induction of opioid-dependent individuals onto buprenorphine and buprenorphine\/naloxone soluble-films","volume":"89","author":"Strain","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib162","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1176\/appi.ajp.2018.17070732","article-title":"A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder","volume":"176","author":"Sullivan","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib163","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1345\/aph.1G276","article-title":"Role of buprenorphine in the management of heroin addiction","volume":"40","author":"Sung","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib164","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1523\/JNEUROSCI.17-07-02585.1997","article-title":"mu-Opioid receptors are localized to extrasynaptic plasma membranes of GABAergic neurons and their targets in the rat nucleus accumbens","volume":"17","author":"Svingos","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib165","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S1054-3589(08)57007-4","article-title":"Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors","volume":"57","author":"Tanda","year":"2009","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib166","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.drugalcdep.2008.03.013","article-title":"Morphine and methadone pre-exposures differently modify brain regional Fos protein expression and locomotor activity responses to morphine challenge in the rat","volume":"97","author":"Taracha","year":"2008","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib167","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.drugalcdep.2005.01.013","article-title":"Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users","volume":"79","author":"Termorshuizen","year":"2005","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib168","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neuropharm.2017.12.006","article-title":"Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats","volume":"131","author":"Tunstall","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib169","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14740338.6.2.125","article-title":"Naloxone treatment in opioid addiction: the risks and benefits","volume":"6","author":"van Dorp","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib170","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cpr.2009.10.006","article-title":"A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid addiction","volume":"30","author":"Veilleux","year":"2010","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib171","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.pnpbp.2013.01.016","article-title":"The atypical dopamine transport inhibitor, JHW 007, prevents amphetamine-induced sensitization and synaptic reorganization within the nucleus accumbens","volume":"44","author":"Velazquez-Sanchez","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib172","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1111\/bph.14353","article-title":"Tolerance to high-internalizing delta opioid receptor agonist is critically mediated by arrestin 2","volume":"175","author":"Vicente-Sanchez","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib173","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00005053-197802000-00004","article-title":"Methadone dose, plasma level, and cross-tolerance to heroin in man","volume":"166","author":"Volavka","year":"1978","journal-title":"J. Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib174","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1001\/archpsyc.1995.03950180042006","article-title":"Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain","volume":"52","author":"Volkow","year":"1995","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib175","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/cn100007x","article-title":"Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib176","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1021\/cn100008c","article-title":"Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib177","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","article-title":"Central nervous system multiparameter optimization desirability: application in drug discovery","volume":"7","author":"Wager","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib178","doi-asserted-by":"crossref","unstructured":"Walsh SL, Comer SD, Lofwall MR, Vince B, Levy-Cooperman N, Kelsh D, Coe MA, Jones JD, Nuzzo PA, Tiberg F, Sheldon B, Kim S. Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry 74: 894-902.","DOI":"10.1001\/jamapsychiatry.2017.1874"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib179","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s002130000439","article-title":"Modulation of intravenous cocaine effects by chronic oral cocaine in humans","volume":"150","author":"Walsh","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib180","article-title":"Treatment of opioid dependence with buprenorphine\/naloxone sublingual tablets: a phase 3 randomized, double-blind, placebo-controlled trial","author":"Wang","year":"2018","journal-title":"Asia Pac. Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib181","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF00735825","article-title":"A dose-response comparison between methadone and morphine self-administration","volume":"47","author":"Werner","year":"1976","journal-title":"Psychopharmacologia"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib182","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/2047-783X-14-1-7","article-title":"Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation - results from a controlled clinical trial","volume":"14","author":"Wieneke","year":"2009","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib183","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF03033808","article-title":"Dopamine and reward: the anhedonia hypothesis 30 years on","volume":"14","author":"Wise","year":"2008","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib185","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/10826084.2017.1400068","article-title":"From narcotic to normalizer: the misperception of methadone treatment and the persistence of prejudice and bias","volume":"53","author":"Woods","year":"2018","journal-title":"Subst. Use Misuse"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib186","series-title":"Management of Substance Abuse: Opiates","author":"World Health Organization (WHO)","year":"2018"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib187","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1527-3458.2007.00013.x","article-title":"Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction","volume":"13","author":"Xi","year":"2007","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib188","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2174\/1874473710801030303","article-title":"Hypothesis-driven medication discovery for the treatment of psychostimulant addiction","volume":"1","author":"Xi","year":"2008","journal-title":"Curr. Drug Abuse Rev."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib189","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/npp.2016.155","article-title":"CTDP-32476: a promising agonist therapy for treatment of cocaine addiction","volume":"42","author":"Xi","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib190","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/alcalc\/37.5.485","article-title":"GABAergic mechanisms underlying opioid reinforcement","volume":"37","author":"Xi","year":"2002","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib191","first-page":"208","article-title":"Dependence potential of buprenorphine studied in rhesus monkeys","volume":"41","author":"Yanagita","year":"1982","journal-title":"NIDA Res. Monogr."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib192","series-title":"Dopamine D\u00ac3r Antagonist Vk4-116 Attenuates Oxycodone Self-Administration and Reinstatement Without Compromising its Antinociceptive Effects","author":"You","year":"2018"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib193","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2017.09.007","article-title":"The novel dopamine D3 receptor antagonists\/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats","volume":"126","author":"You","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib194","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1360-0443.1971.tb02387.x","article-title":"Duration of methadone induced cross-tolerance to heroin","volume":"66","author":"Zaks","year":"1971","journal-title":"Br. J. Addict. Alcohol Other Drugs"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib196","doi-asserted-by":"crossref","first-page":"7225","DOI":"10.1523\/JNEUROSCI.22-16-07225.2002","article-title":"Rewarding and psychomotor stimulant effects of endomorphin-1: anteroposterior differences within the ventral tegmental area and lack of effect in nucleus accumbens","volume":"22","author":"Zangen","year":"2002","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.04.015_bib197","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/npp.2017.41","article-title":"The novel modafinil analog, JJC8-016, as a potential cocaine abuse pharmacotherapeutic","volume":"42","author":"Zhang","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib198","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.neuroscience.2008.09.039","article-title":"Mu opioid receptor knockdown in the substantia nigra\/ventral tegmental area by synthetic small interfering RNA blocks the rewarding and locomotor effects of heroin","volume":"158","author":"Zhang","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2019.04.015_bib199","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1124\/jpet.108.146142","article-title":"Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil","volume":"329","author":"Zolkowska","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819300012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819300012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T06:59:31Z","timestamp":1758437971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819300012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":197,"alternative-id":["S0028390819300012"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.04.015","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735597479.793559850","asserted-by":"object"}]},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107609"}}